Rockefeller Capital Management
SPRY icon

Rockefeller Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Rockefeller Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.7K Hold
5,454
– – ﹤0.01% 3430
2026
Q1 		$43.8K Buy
5,454
+3,560
+188% +$34.1K ﹤0.01% 3349
2025
Q4 		$22.1K Buy
1,894
+894
+89% +$8.69K ﹤0.01% 3469
2025
Q3 		$10.1K Buy
+1,000
New +$14.4K ﹤0.01% 3643

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Rockefeller Capital Management's SPRY Position: Q2 2026 in Review

Rockefeller Capital Management held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 5,454 shares worth $43.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3430.

Rockefeller Capital Management first reported a position in SPRY in Q3 2025 and has held it in 4 quarters since. The position peaked at $43.8K in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Rockefeller Capital Management held 5,454 shares of ARS Pharmaceuticals worth $43.7K as of Q2 2026.
  • Rockefeller Capital Management left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3430 holding.
  • Rockefeller Capital Management first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's ARS Pharmaceuticals position peaked at $43.8K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.